<scratchpad>
The user wants a chronological list of medical visits. I need to go through the document and extract relevant information for each valid medical encounter.

Here's my plan:
1.  **Scan through the document section by section.**
2.  **Identify potential medical encounters.** This includes "Provider Note", "Telephone Encounter Note" (if clinical), "Orders Only Encounter" (if clinical lab/imaging orders), "Specialist Consultation", "Office Visit Progress Note", and "Lab Reports" (as separate entries if they are distinct events from a visit).
3.  **Apply inclusion/exclusion criteria:**
    *   Must have at least a Facility Name OR Provider Name.
    *   Exclude legal events (FAX to attorney), administrative calls (scheduling, billing), provider lists, consent forms.
    *   Lab reports are valid if they are distinct events (e.g., a lab collection date separate from a visit, or if the report itself is the primary record of a medical event).
4.  **Extract required fields for each valid encounter.**
    *   Type of Visit
    *   Facility Name
    *   Provider Name
    *   Subjective/HPI/CC/Hospital Course
    *   Objective/PE
    *   Social
    *   Labs (significant abnormal results)
    *   Surgery/Procedure
    *   Imaging (findings)
    *   Diagnoses
    *   Plan/Assessment
    *   MSS
    *   Medication(s)
    *   Referrals
    *   Source References
5.  **Sort chronologically.**
6.  **Format according to the specified rules.** Pay close attention to headings, bullet points, and the exact order of fields.

**Initial Pass - Identifying Potential Encounters & Filtering:**

*   **Provider Note (Liu, Andrew K, MD) - May 2, 2024:** Valid clinical visit.
    *   Date: 05/02/2024
    *   Facility: Bridgewater Psychiatry Walnut Street
    *   Provider: Liu, Andrew K, MD
    *   Type: Telemedicine / Behavioral Health Outpatient Clinic Follow-up
    *   Source: Page 1 of 12
*   **National Clinical Laboratories - LIPID SCREEN & HEMOGLOBIN A1C - Collection Date: 05/02/2024:** This lab collection happened on the same day as the visit with Dr. Liu. I will integrate the lab results into the 05/02/2024 visit entry, as they were ordered by Dr. Liu and collected on the same day.
    *   Source: Page 4 of 12
*   **Bridgewater Health - Patient Billing Inquiry - 06/15/2024:** Administrative/billing. Exclude.
*   **Bridgewater Health - Provider Directory Update Notification - 07/01/2024:** Administrative list. Exclude.
*   **Bridgewater Health - Department of Radiology - Chest X-Ray Report - 08/19/2023:** This date is outside the implied scope (01/01/2024 to present, based on the legal records request, though the document itself has earlier dates). The prompt asks for a chronological list of medical visits from the *provided records*. The X-ray is a medical event.
    *   Date: 08/19/2023
    *   Facility: Bridgewater Health - Department of Radiology
    *   Provider: Mehta, Sunita, MD (Radiologist)
    *   Type: Imaging Study (Chest X-Ray)
    *   Source: Page 10 of 12
*   **Provider Note (Nair, Kavitha, MD) - 2024-11-14:** Valid clinical visit.
    *   Date: 11/14/2024
    *   Facility: Bridgewater Psychiatry Walnut Street (implied from previous notes and provider directory update)
    *   Provider: Nair, Kavitha, MD
    *   Type: Telemedicine / Psychiatry Follow Up
    *   Source: Page 1 of 12 (second note)
*   **Allied Diagnostics - HEME PROFILE + ELECT DIFF - Collection Date: 11/14/2024:** This lab collection happened on the same day as the visit with Dr. Nair. I will integrate the lab results into the 11/14/2024 visit entry.
    *   Source: Page 4 of 12
*   **AETNA HEALTH - PRIOR AUTHORIZATION REQUEST - FAXED ON: 11/20/2024:** Administrative/insurance. Exclude.
*   **Bridgewater Health - Scheduling Communication Log - 12/10/2024:** Administrative/scheduling. Exclude.
*   **Bridgewater University Health System - Specialist Consultation (Brennan, Thomas E, MD) - December 17, 2024:** Valid clinical visit.
    *   Date: 12/17/2024
    *   Facility: Bridgewater Heart and Vascular Center Briarwood
    *   Provider: Brennan, Thomas E, MD
    *   Type: Specialist Consultation (Cardiology/Metabolic)
    *   Source: Page 2 of 12
*   **MyBridgewaterHealth Secure Message (from patient to Dr. Reyes) - 12/26/2024:** Patient communication, not a clinical visit. Exclude.
*   **Bridgewater Adolescent and Young Adult Medicine Briarwood - Telephone Encounter (Reyes, Gabriela, MD) - 12/26/2024:** This is a clinical interaction where a concern was addressed and a plan for follow-up was initiated (message routed to Dr. Reyes). This counts as a medical event.
    *   Date: 12/26/2024
    *   Facility: Bridgewater Adolescent and Young Adult Medicine Briarwood
    *   Provider: Reyes, Gabriela, MD (Provider on Call)
    *   Type: Telephone Encounter
    *   Source: Page 3 of 12
*   **Telephone Encounter Note (Nair, Kavitha, MD) - 27-Dec-24:** Valid clinical interaction where medication was adjusted based on lab results.
    *   Date: 12/27/2024
    *   Facility: Bridgewater Psychiatry Walnut Street (implied)
    *   Provider: Nair, Kavitha, MD
    *   Type: Telephone Encounter / Medication Adjustment
    *   Source: Page 1 of 12 (third note)
*   **Orders Only Encounter (Brennan, Thomas E, MD) - Jan 7, 2025:** Valid clinical event (ordering labs).
    *   Date: 01/07/2025
    *   Facility: Bridgewater Heart and Vascular Center Briarwood (implied from provider)
    *   Provider: Brennan, Thomas E, MD
    *   Type: Orders Only Encounter (Lab Orders)
    *   Source: Page 3 of 12
*   **FAX COVER SHEET (to Eleanor Caldwell, Esq.) - January 16, 2025:** Legal/administrative. Exclude.
*   **Orders Only Encounter (Liu, Andrew K, MD) - 2025-01-27:** Valid clinical event (lab review).
    *   Date: 01/27/2025
    *   Facility: Bridgewater Psychiatry Walnut Street (implied from provider)
    *   Provider: Liu, Andrew K, MD
    *   Type: Orders Only Encounter (Lab Review)
    *   Source: Page 2 of 12
*   **Allied Diagnostics - HEME PROFILE + ELECT DIFF - Collection Date: 01/27/2025:** This lab collection happened on the same day as the lab review by Dr. Liu. I will integrate the lab results into the 01/27/2025 entry.
    *   Source: Page 5 of 12
*   **Office Visit Progress Note (Reyes, Gabriela, MD) - February 10, 2025:** Valid clinical visit.
    *   Date: 02/10/2025
    *   Facility: Bridgewater Adolescent and Young Adult Medicine Briarwood
    *   Provider: Reyes, Gabriela, MD
    *   Type: Office Visit
    *   Source: Page 3 of 12
*   **Bridgewater Health - Patient Account Statement - 02/28/2025:** Administrative/billing. Exclude.
*   **Consent Forms (01/05/2023, 04/15/2023):** Administrative/legal. Exclude.

**Chronological Ordering and Detail Extraction:**

1.  **08/19/2023:** Chest X-Ray
2.  **05/02/2024:** Bridgewater Psychiatry Walnut Street - Dr. Liu
3.  **11/14/2024:** Bridgewater Psychiatry Walnut Street - Dr. Nair
4.  **12/17/2024:** Bridgewater Heart and Vascular Center Briarwood - Dr. Brennan
5.  **12/26/2024:** Bridgewater Adolescent and Young Adult Medicine Briarwood - Dr. Reyes (Telephone)
6.  **12/27/2024:** Bridgewater Psychiatry Walnut Street - Dr. Nair (Telephone)
7.  **01/07/2025:** Bridgewater Heart and Vascular Center Briarwood - Dr. Brennan (Orders Only)
8.  **01/27/2025:** Bridgewater Psychiatry Walnut Street - Dr. Liu (Orders Only)
9.  **02/10/2025:** Bridgewater Adolescent and Young Adult Medicine Briarwood - Dr. Reyes (Office Visit)

Now, I will go through each identified encounter and extract the specific details for each field, ensuring strict adherence to the output format and field order. I will pay close attention to the "Labs" section, only listing *significant abnormal results*.

**Detailed Extraction for each entry:**

**08/19/2023**
*   **Type of Visit:** Imaging Study (Chest X-Ray)
*   **Facility Name:** Bridgewater Health - Department of Radiology
*   **Provider Name:** Sunita Mehta, MD
*   **Subjective/HPI/CC/Hospital Course:** 24-year-old male with cough. Rule out pneumonia.
*   **Imaging:** No acute cardiopulmonary process. Cardiomediastinal silhouette within normal limits. Lungs clear. No focal consolidation, pleural effusion, or pneumothorax.
*   **Source References:** (10E Page 10 of 12)

**05/02/2024**
*   **Type of Visit:** Telemedicine / Behavioral Health Outpatient Clinic Follow-up
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Andrew K Liu, MD
*   **Subjective/HPI/CC/Hospital Course:** Return visit for medication management. Psychiatric symptoms stable since November 2023. Unemployed, actively searching for job, taking electrician classes. Sleep "ok" (midnight-12/1 PM). Denies appetite changes, notes 3-4 lb weight increase. Exercise intermittent. Denies clozapine side effects. Continues to endorse chronic delusions (thought broadcasting, thought insertion). Denies suicidal/homicidal ideation.
*   **Objective/PE:** Grooming appropriate, fair effort to appearance. Eye contact fair. No psychomotor agitation/retardation, no choreoathetoid movements. Speech normal rate/rhythm. Mood "Ok." Affect predominantly blunted, intermittently reactive. Thought process linear, goal-directed. Chronic delusions (thought broadcasting, thought insertion). Denies SI/HI. Denies auditory/visual hallucinations, not responding to internal stimuli. Alert and oriented. Insight fair to limited, judgment fair. Weight 218 lbs (Dr. Fischer estimate). Last recorded weight 12/19/23 was 231 lbs, BMI 34.11 kg/m². No EPS.
*   **Social:** Currently out of work, pursuing vocational training in electrical work. Resides with parents. Expressed interest in SSI benefits. Primary social outlet is online gaming.
*   **Labs:**
    *   Total Cholesterol: 220 mg/dL (H)
    *   Triglycerides: 397 mg/dL (H)
    *   HDL Cholesterol: 27 mg/dL (L)
    *   VLDL Cholesterol Cal: 71 mg/dL (H)
    *   LDL Cholesterol Calc: 122 mg/dL (H)
*   **Diagnoses:** Schizophrenia, Paranoid type (F20.0); Hyperlipidemia; Long term current use of antipsychotic medication (Z79.899).
*   **Plan/Assessment:** Continue clozapine 250 mg daily. Discussed Caplyta. Metabolic monitoring: Orders for Hemoglobin A1c and Lipid Panel. Continue monthly CBC checks for ANC. Psychoeducation on lifestyle modifications for weight management (exercise, healthier diet, ketogenic diet mentioned). Encourage follow-up with metabolic specialist. Follow-up in 5-6 months. Counseled on clozapine side effects.
*   **Medication(s):** Clozapine 100 mg tablet, take 2.5 tablets by mouth daily; Omega-3 fatty acids 1000 mg capsule, take 2 capsules by mouth daily.
*   **Referrals:** Continue follow-up with PCP for hypertriglyceridemia. Follow up with metabolic specialist.
*   **Source References:** (10E Page 1 of 12), (10E Page 4 of 12)

**11/14/2024**
*   **Type of Visit:** Telemedicine / Psychiatry Follow Up
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Kavitha Nair, MD
*   **Subjective/HPI/CC/Hospital Course:** Return visit for medication management. Period of stability, no significant changes to mental health or life circumstances. Lives at home with parents, enrolled in electrician certification classes. Not currently employed. Sleep and mood unchanged. Occasional, fleeting paranoid thoughts (feeling watched/monitored) a couple of times per month. Morning grogginess attributed to clozapine, denies other side effects. Denies suicidal/homicidal ideation.
*   **Objective/PE:** Attention to hygiene/grooming appropriate. No abnormal motor activity. Cooperative, polite. Speech normal rate/rhythm. Mood "Fine." Affect mildly blunted but reactive. Thought process linear, organized, goal-directed. Denies SI/HI. Mild paranoia, no other overt delusions/grandiosity. Denies auditory/visual hallucinations. Grossly oriented. Insight/judgment fair. Euthymic with slightly blunted affect. No AVH/delusions, no RIS, no SI/HI.
*   **Social:** No problematic use of alcohol, cannabis, or nicotine reported.
*   **Labs:** ANC (Absolute Neutrophil Count) is within normal limits for clozapine monitoring. (WBC 5.3 K/uL, Neutrophils (Absolute) 3.5 K/uL)
*   **Diagnoses:** Paranoid schizophrenia (CMS-HCC) F20.0; Long term current use of antipsychotic medication Z79.89.
*   **Plan/Assessment:** Continue clozapine 250 mg daily. Monitor response/tolerability. Order for Clozapine level with next labs. Continue monthly ANC monitoring. Return for follow-up in ~6 months. Psychoeducation provided. Encouraged continued follow-up with PCP. Risks/benefits of clozapine discussed. Treatment plan appropriate for outpatient care, no acute risk.
*   **Medication(s):** Clozapine 250 mg tablet, take 2.5 tablets by mouth daily at bedtime for 180 days.
*   **Source References:** (10E Page 1 of 12), (10E Page 4 of 12)

**12/17/2024**
*   **Type of Visit:** Specialist Consultation
*   **Facility Name:** Bridgewater Heart and Vascular Center Briarwood
*   **Provider Name:** Thomas E Brennan, MD
*   **Subjective/HPI/CC/Hospital Course:** Follow-up appointment for evaluation of hyperlipidemia. Patient attended with mother.
*   **Diagnoses:** Combined hyperlipidemia; Class 1 obesity with serious comorbidity, BMI of 34.0 to 34.9 in an adult, unspecified obesity type.
*   **Plan/Assessment:** Recommendations for management of combined hyperlipidemia and obesity. Discussion regarding dietary modification, regular physical activity, and potential future pharmacologic interventions if lifestyle changes insufficient. Patient and mother verbalized understanding. Follow up as needed.
*   **Source References:** (10E Page 2 of 12)

**12/26/2024**
*   **Type of Visit:** Telephone Encounter
*   **Facility Name:** Bridgewater Adolescent and Young Adult Medicine Briarwood
*   **Provider Name:** Gabriela Reyes, MD
*   **Subjective/HPI/CC/Hospital Course:** Patient expressed concern regarding hair loss. Message routed to Dr. Reyes for review to determine if appointment needed. Patient advised they would call him back.
*   **Source References:** (10E Page 3 of 12)

**12/27/2024**
*   **Type of Visit:** Telephone Encounter / Medication Adjustment
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Kavitha Nair, MD
*   **Subjective/HPI/CC/Hospital Course:** Patient's mother called regarding recent lab results. Clozapine level slightly above 600.
*   **Plan/Assessment:** Daily dose of clozapine reduced from 250 mg to 225 mg. Recheck clozapine level in one month, with next scheduled ANC. Mother verbalized understanding.
*   **Source References:** (10E Page 1 of 12)

**01/07/2025**
*   **Type of Visit:** Orders Only Encounter (Lab Orders)
*   **Facility Name:** Bridgewater Heart and Vascular Center Briarwood
*   **Provider Name:** Thomas E Brennan, MD
*   **Diagnoses:** Combined hyperlipidemia (E78.2); Insulin resistance (R73.03).
*   **Plan/Assessment:** New laboratory orders entered: LIPID PANEL W/ REFLEX TO DIRECT LDL, INSULIN, FASTING, COMPREHENSIVE METABOLIC PANEL. Patient to complete prior to next follow-up.
*   **Source References:** (10E Page 3 of 12)

**01/27/2025**
*   **Type of Visit:** Orders Only Encounter (Lab Review)
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Andrew K Liu, MD
*   **Labs:** ANC (Absolute Neutrophil Count) is within normal limits for clozapine monitoring. (WBC 4.4 K/uL, Neutrophils (Absolute) 2.6 K/uL)
*   **Diagnoses:** Paranoid schizophrenia (CMS-HCC) [F20.0]; Long term current use of antipsychotic medication [Z79.899].
*   **Plan/Assessment:** Recent lab results for HEME PROFILE + ELECT DIFF reviewed and acknowledged. No additional clinical findings or changes to plan of care documented.
*   **Source References:** (10E Page 2 of 12), (10E Page 5 of 12)

**02/10/2025**
*   **Type of Visit:** Office Visit
*   **Facility Name:** Bridgewater Adolescent and Young Adult Medicine Briarwood
*   **Provider Name:** Gabriela Reyes, MD
*   **Subjective/HPI/CC/Hospital Course:** Patient presents with mother, primary concern hair loss, occurring for some time. Attempted OTC remedies (rosemary oil, topical minoxidil) without benefit. Family history of receding hair lines (mother's side) and male pattern baldness (father's side). Hypertriglyceridemia followed by Dr. Brennan, off Lovaza, focusing on diet/exercise. H/o paranoid schizophrenia, followed by Bridgewater psychiatry, primary medication clozapine (requires monthly CBC monitoring). Mentioned recent challenges with clozaril prescription fill.
*   **Objective/PE:** Vitals: BP 111/76, Pulse 84, Temp 97.6 F, Weight 227 lbs (103 kg), BMI 32.39 kg/m², SpO2 97% RA. Mouth/Throat: Mucous membranes moist. Eyes: Conjunctivae normal. Cardiovascular: HR/rhythm normal, heart sounds normal. Pulmonary: Respiratory effort normal, normal breath sounds. Skin: Warm, dry, no rash. Scalp: Receding hair line anteriorly, no bald patches. Neurological: No focal deficits. Psychiatric: Mood/behavior normal.
*   **Social:** In process of applying for SSI, working with attorney Eleanor Caldwell.
*   **Diagnoses:** Hair loss (L65.9) (likely androgenic alopecia); Hypertriglyceridemia (E78.1); Paranoid schizophrenia (F20.0).
*   **Plan/Assessment:** Begin trial of oral minoxidil 1.25 mg daily. Follow-up in 2 months. Reinforced importance of lifestyle factors for hypertriglyceridemia. Clozapine management and monitoring to continue under Bridgewater psychiatry. Return in ~2 years for general follow-up/medication check, or sooner as needed.
*   **Medication(s):** Oral minoxidil 1.25 mg daily (new).
*   **Source References:** (10E Page 3 of 12)

Double-check all rules:
-   Output ONLY the final “Medical Chronology” section. (Yes)
-   Formatting: STRICT markdown structure. Every bullet point on NEW LINE. No run-on paragraphs. (Will ensure this)
-   Do NOT include: `<scratchpad>`, `analysis`, `reasoning`. (Yes)
-   Heading Level 2: `## Date of Medical Visit: MM/DD/YYYY` (Yes)
-   Heading Level 3: `### MM/DD/YYYY` (or `### MM/YYYY`) (Yes)
-   Content: Bullet points (`*`). (Yes)
-   Order: Exact field order. (Yes)
-   Same-day visits: Multiple `###` sections under same `##` date heading if distinct. (Not applicable here, labs are integrated if on same day as visit, or separate if distinct lab collection event). The lab collections on 05/02/2024, 11/14/2024, and 01/27/2025 are on the same day as a clinical encounter or lab review, so I will integrate the *results* into those entries. The "Orders Only Encounter" on 01/07/2025 is distinct as it's just ordering labs, not a collection or review.
-   Inclusion: At least one of Facility Name or Provider Name. (All included entries meet this).
-   Medical Only: Exclude legal, pharmacy fills, admin, scheduling, billing, provider lists. (Done).
-   Date Accuracy: "Date of Service" only. MM/YYYY if day missing. (All dates are specific days).

Looks good. I will now generate the output.## Date of Medical Visit: 08/19/2023
### 08/19/2023
*   **Type of Visit:** Imaging Study (Chest X-Ray)
*   **Facility Name:** Bridgewater Health - Department of Radiology
*   **Provider Name:** Sunita Mehta, MD
*   **Subjective/HPI/CC/Hospital Course:** 24-year-old male with cough. Rule out pneumonia.
*   **Imaging:** No acute cardiopulmonary process. The cardiomediastinal silhouette is within normal limits for size and contour. The pulmonary vasculature is unremarkable. The lungs are clear. There is no evidence of focal consolidation, pleural effusion, or pneumothorax. Visualized osseous structures of the thorax are intact and without acute abnormality. The soft tissues of the chest wall are unremarkable.
*   **Source References:** (10E Page 10 of 12)

## Date of Medical Visit: 05/02/2024
### 05/02/2024
*   **Type of Visit:** Telemedicine / Behavioral Health Outpatient Clinic Follow-up
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Andrew K Liu, MD
*   **Subjective/HPI/CC/Hospital Course:** Return visit for medication management. Psychiatric symptoms stable since November 2023. Unemployed but actively searching for a job while taking classes to become an electrician. Sleep "ok" (midnight-12/1 PM). Denies recent changes in appetite but notes a weight increase of three to four pounds. Exercise is intermittent. Denies any side effects from clozapine medication. Continues to endorse chronic delusions, specifically thought broadcasting and thought insertion. Denies any suicidal or homicidal ideation.
*   **Objective/PE:** Mental Status Examination: Grooming appropriate, fair effort to appearance. Eye contact fair. No psychomotor agitation or retardation, no choreoathetoid movements. Speech normal rate and rhythm. Mood "Ok." Affect predominantly blunted, intermittently reactive. Thought process linear and goal-directed. Content of thoughts includes chronic delusions, with endorsement of thought broadcasting and thought insertion. Denies suicidal or homicidal ideation. Perception: Denies auditory or visual hallucinations and does not appear to be responding to internal stimuli. Cognition: Alert and oriented. Insight fair to limited, judgment fair. Weight estimated at 218 lbs. Last recorded weight on 12/19/23 was 231 lbs, with a BMI of 34.11 kg/m². Speech mostly expressive. No EPS noted.
*   **Social:** Currently out of work and pursuing vocational training in electrical work. Resides with parents. Expressed interest in applying for SSI benefits. Primary social outlet is online gaming.
*   **Labs:**
    *   Total Cholesterol: 220 mg/dL (H)
    *   Triglycerides: 397 mg/dL (H)
    *   HDL Cholesterol: 27 mg/dL (L)
    *   VLDL Cholesterol Cal: 71 mg/dL (H)
    *   LDL Cholesterol Calc: 122 mg/dL (H)
*   **Diagnoses:** Schizophrenia, Paranoid type (F20.0); Hyperlipidemia; Long term current use of antipsychotic medication (Z79.899).
*   **Plan/Assessment:** Continue current regimen of clozapine at 250 mg daily. Discussed potential benefits of considering Caplyta in the future. Metabolic Monitoring: Orders placed for a Hemoglobin A1c and a Lipid Panel. Continue monthly CBC checks for ANC monitoring. Counseling: Provided psychoeducation regarding lifestyle modifications for weight management, including encouragement to increase exercise and adopt a healthier diet. Possibility of a ketogenic diet mentioned. Encouraged follow up with metabolic specialist again. Follow-up: Patient to return to clinic in 5-6 months. Counseled on clozapine side effects.
*   **Medication(s):** Clozapine 100 mg tablet, take 2.5 tablets by mouth daily; Omega-3 fatty acids 1000 mg capsule, take 2 capsules by mouth daily.
*   **Referrals:** Continue follow-up with PCP for hypertriglyceridemia. Follow up with metabolic specialist as previously recommended.
*   **Source References:** (10E Page 1 of 12), (10E Page 4 of 12)

## Date of Medical Visit: 11/14/2024
### 11/14/2024
*   **Type of Visit:** Telemedicine / Psychiatry Follow Up
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Kavitha Nair, MD
*   **Subjective/HPI/CC/Hospital Course:** Patient presents for a return visit and medication management. Indicates a period of stability, reporting no significant changes to mental health or overall life circumstances. Continues to live at home with parents and is enrolled in classes for an electrician certification. Not currently employed. Sleep and mood unchanged. Reports experiencing occasional, fleeting paranoid thoughts a couple of times per month, involving feelings of being watched or monitored. Notes some morning grogginess attributed to clozapine but denies any other side effects. Explicitly denies any suicidal or homicidal ideation.
*   **Objective/PE:** Mental Status Exam: Attention to hygiene and grooming appropriate. No abnormal motor activity observed. Cooperative and polite. Speech normal in rate and rhythm. Mood "Fine." Affect mildly blunted but reactive. Thought process linear, organized, and goal-directed. Denies SI/HI. Mild paranoia noted, but no other overt delusions or grandiosity. Denies any auditory or visual hallucinations. Grossly oriented. Insight and judgment fair. Euthymic with a slightly blunted affect. No AVH/delusions, no RIS, no SI/HI.
*   **Social:** No problematic use of alcohol, cannabis, or nicotine reported.
*   **Labs:** ANC (Absolute Neutrophil Count) is within normal limits for clozapine monitoring (Neutrophils (Absolute) 3.5 K/uL).
*   **Diagnoses:** Paranoid schizophrenia (CMS-HCC) F20.0; Long term current use of antipsychotic medication Z79.89.
*   **Plan/Assessment:** Continue clozapine 250 mg by mouth daily. Monitor response and tolerability. Order placed to obtain a Clozapine level with next set of labs. Continue monthly ANC monitoring. Patient to return for follow-up in approximately 6 months. Provided psychoeducation. Encouraged continued follow-up with PCP for general health maintenance. Risks and benefits of clozapine discussed. Current treatment plan remains appropriate for outpatient care. Not deemed to be at any acute risk.
*   **Medication(s):** Clozapine 250 mg tablet, take 2.5 tablets by mouth daily at bedtime for 180 days.
*   **Source References:** (10E Page 1 of 12), (10E Page 4 of 12)

## Date of Medical Visit: 12/17/2024
### 12/17/2024
*   **Type of Visit:** Specialist Consultation
*   **Facility Name:** Bridgewater Heart and Vascular Center Briarwood
*   **Provider Name:** Thomas E Brennan, MD
*   **Subjective/HPI/CC/Hospital Course:** Follow-up appointment stemming from an original referral for a more detailed evaluation of hyperlipidemia. Patient attended with his mother.
*   **Diagnoses:** Combined hyperlipidemia; Class 1 obesity with serious comorbidity, body mass index (BMI) of 34.0 to 34.9 in an adult, unspecified obesity type.
*   **Plan/Assessment:** Recommendations provided for management of combined hyperlipidemia and obesity. Detailed discussion regarding dietary modification, importance of regular physical activity, and potential future pharmacologic interventions if lifestyle changes are not sufficient. Patient and mother verbalized understanding. Follow up as needed.
*   **Source References:** (10E Page 2 of 12)

## Date of Medical Visit: 12/26/2024
### 12/26/2024
*   **Type of Visit:** Telephone Encounter
*   **Facility Name:** Bridgewater Adolescent and Young Adult Medicine Briarwood
*   **Provider Name:** Gabriela Reyes, MD
*   **Subjective/HPI/CC/Hospital Course:** Patient expressed a concern regarding hair loss. Message routed to Dr. Reyes's clinical inbox for review and to determine if an appointment is needed. Patient was advised they would call him back.
*   **Source References:** (10E Page 3 of 12)

## Date of Medical Visit: 12/27/2024
### 12/27/2024
*   **Type of Visit:** Telephone Encounter / Medication Adjustment
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Kavitha Nair, MD
*   **Subjective/HPI/CC/Hospital Course:** Telephone call received from the patient's mother regarding recent laboratory results. She stated that the clozapine level came back with a value slightly above 600.
*   **Plan/Assessment:** Based on information, decision made to adjust patient's medication. Daily dose of clozapine reduced from 250 mg to 225 mg. Plan to recheck clozapine level in one month, to be drawn at same time as next scheduled ANC. Mother verbalized understanding.
*   **Source References:** (10E Page 1 of 12)

## Date of Medical Visit: 01/07/2025
### 01/07/2025
*   **Type of Visit:** Orders Only Encounter (Lab Orders)
*   **Facility Name:** Bridgewater Heart and Vascular Center Briarwood
*   **Provider Name:** Thomas E Brennan, MD
*   **Diagnoses:** Combined hyperlipidemia (E78.2); Insulin resistance (R73.03).
*   **Plan/Assessment:** New laboratory orders entered: LIPID PANEL W/ REFLEX TO DIRECT LDL, INSULIN, FASTING, COMPREHENSIVE METABOLIC PANEL. Patient to complete prior to next follow-up.
*   **Source References:** (10E Page 3 of 12)

## Date of Medical Visit: 01/27/2025
### 01/27/2025
*   **Type of Visit:** Orders Only Encounter (Lab Review)
*   **Facility Name:** Bridgewater Psychiatry Walnut Street
*   **Provider Name:** Andrew K Liu, MD
*   **Labs:** ANC (Absolute Neutrophil Count) is within normal limits for clozapine monitoring (Neutrophils (Absolute) 2.6 K/uL).
*   **Diagnoses:** Paranoid schizophrenia (CMS-HCC) [F20.0]; Long term current use of antipsychotic medication [Z79.899].
*   **Plan/Assessment:** Recent lab results for HEME PROFILE + ELECT DIFF were reviewed and acknowledged by the provider. No additional clinical findings or changes to the plan of care were documented for this date.
*   **Source References:** (10E Page 2 of 12), (10E Page 5 of 12)

## Date of Medical Visit: 02/10/2025
### 02/10/2025
*   **Type of Visit:** Office Visit
*   **Facility Name:** Bridgewater Adolescent and Young Adult Medicine Briarwood
*   **Provider Name:** Gabriela Reyes, MD
*   **Subjective/HPI/CC/Hospital Course:** Patient, with mother, presents with primary concern of hair loss, occurring for some time. Attempted over-the-counter remedies including rosemary oil and topical minoxidil, but no benefit. Family history of receding hair lines on mother's side and male pattern baldness on father's side. Hypertriglyceridemia followed by Dr. Brennan, currently off Lovaza and focusing on diet and exercise. History of paranoid schizophrenia, followed by Bridgewater psychiatry, primary medication clozapine (requires monthly CBC monitoring). Mentioned some recent challenges with getting his clozaril prescription filled.
*   **Objective/PE:** Vitals: Blood pressure 111/76 mmHg, Pulse 84 bpm, Temperature 97.6 F, Weight 227 lbs (103 kg), BMI 32.39 kg/m², SpO2 97% on room air. Physical Exam: Mouth/Throat: Mucous membranes moist. Eyes: Conjunctivae appear normal. Cardiovascular: Heart rate and rhythm normal, heart sounds normal. Pulmonary: Respiratory effort normal, normal breath sounds. Skin: Warm and dry, no rash. Scalp: Receding hair line, anteriorly. No bald patches. Neurological: No focal deficits identified. Psychiatric: Mood and behavior appear normal.
*   **Social:** Patient is in the process of applying for SSI and is working with an attorney, Eleanor Caldwell.
*   **Diagnoses:** Hair loss (L65.9) (likely androgenic alopecia); Hypertriglyceridemia (E78.1); Paranoid schizophrenia (F20.0).
*   **Plan/Assessment:** Begin trial of oral minoxidil at a dose of 1.25 mg daily. Follow-up appointment scheduled in 2 months to evaluate for response. Reinforced importance of lifestyle factors for hypertriglyceridemia. Management of clozapine and associated monitoring to continue under Bridgewater psychiatry team. Return in approximately 2 years for a general follow-up and medication check, or sooner as needed.
*   **Medication(s):** Oral minoxidil 1.25 mg daily.
*   **Source References:** (10E Page 3 of 12)